Prescient Therapeutics Ltd has released a press release.
Clinical Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- PTX Broker Presentation
- European Patent Granted for PTX-200
- Kansas University Joins PTXs AML Trial
- FDA Grants Orphan Drug Designation for PTX-200 in AML
- March 2017 Appendix 4C - Quarterly
Later from Prescient Therapeutics
- Novel PTX-100 Cancer Approach Published in Nature
- June 2017 Appendix 4C - Quarterly
- Appendix 4E and 2017 Annual Report
- Prescient to resume AML trial
- PTX-100 to Re-enter Trials in Hematology Niche
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics